ANIP - ANI Pharmaceuticals Q2 mixed earnings; raises FY 2022 revenue guidance for Cortrophin
- ANI Pharmaceuticals press release ( NASDAQ: ANIP ): Q2 Non-GAAP EPS of $0.13 misses by $0.09 .
- Revenue of $73.9M (+52.0% Y/Y) beats by $1.93M .
- Adjusted non-GAAP EBITDA of $9.9M.
- Full-Year 2022 Guidance : Reiterates total company net revenue guidance of $295 million to $315 million vs. consensus of $304.53M; adjusted non-GAAP EBITDA guidance of $54 million to $60 million; adjusted non-GAAP earnings per share between $1.34 and $1.62 vs. consensus of $1.43.
-
The company raises its revenue guidance for Cortrophin to be in the range of $40 million to $45 million from its previous guidance of $35 million to $40 million.
For further details see:
ANI Pharmaceuticals Q2 mixed earnings; raises FY 2022 revenue guidance for Cortrophin